La farmacéutica danesa acusa a su competidora estadounidense de comparar la eficacia de sus medicamentos en su dosis más alta con una menor de Wegovy y Ozempic

The lawsuit, filed in federal court Tuesday, accuses Eli Lilly of using outdated data in advertising campaigns.

FARMACEUTSKA tvrtka Novo Nordisk tuži konkurenta Eli Lilly zbog, kako navodi, lažnog prikazivanja njegovih lijekova za mršavljenje kao superiornijih na temelju zastarjelih studija.

Eli Lilly não responde a pedido de comentário após processo da Novo Nordisk nos EUA

Novo alleges Lilly compared the highest approved doses of its medicines with lower doses of Novo’s Wegovy and Ozempic while omitting newer, higher-dose versions that Novo says…

Novo Nordisk claims Eli Lilly aired misleading ads comparing the pharma companies' respective weight-loss drugs, Wegovy and Zepbound.

Novo Nordisk has sued Eli Lilly in a U.S. court. The Danish company accuses Lilly of false advertising for its weight-loss medicines. Novo claims Lilly compared lower doses of its…

"Through this action, Novo Nordisk is seeking a permanent injunction requiring Lilly to pull its misleading comparative advertising across all platforms... "

Danish pharmaceuticals heavyweight Novo Nordisk said Tuesday it is suing its arch US rival, Eli Lilly, over "false and materially misleading" adverts for their competing…

Novo Nordisk, fabricante del medicamento contra la obesidad Ozempic, demanda a su rival Eli Lilly por publicidad engañosa.

Le duel entre les leaders du marché de l'anti-obésité se poursuit devant les tribunaux américains. Le fabricant du Wegovy a saisi la justice, estimant que les publicités pour…

Empresa dinamarquesa alega que a rival usou comparações com doses antigas do Wegovy para favorecer o Zepbound e pede a suspensão imediata da campanha

Das dänische Unternehmen sieht sich in einer Werbung seines US-Konkurrenten falsch dargestellt und klagt. Worum es in den Streit geht.

La casa farmaceutica danese accusa la rivale americana di aver promosso Zepbound e Mounjaro con confronti «falsi e fuorvianti» rispetto a Wegovy e Ozempic. Nel mirino una campagna…

La compañía danesa critica las comparaciones de sus tratamientos con los medicamentos estrella de su competidor estadounidense, Mounjaro y Zepbound

La multinazionale danese Novo Nordisk, che produce l’Ozempic e il Wegovy – due farmaci utilizzati per contrastare il diabete e l’obesità (cambiano i dosaggi) – ha fatto causa…

Novo Nordisk has claimed that Eli Lilly is using bad data to compare the companies' weight-loss and diabetes products in its ads.

La farmacéutica danesa acusa a su competidora estadounidense de comparar la eficacia de sus medicamentos en su dosis más alta con una menor de Wegovy y Ozempic

Novo Nordisk cita in giudizio Eli Lilly: sotto accusa campagne basate su dati superati per esagerare l'efficacia dei farmaci GLP-1

Novo Nordisk has filed a lawsuit against Eli Lilly, alleging false advertising and deceptive marketing for Zepbound and Mounjaro treatments.

The lawsuit alleges that Eli Lilly misled consumers by using outdated clinical trial data to make its drugs appear more effective than Novo's.